A novel technique for ultra-low contrast administration during angiography or intervention

Contrast‐induced nephropathy (CIN) after coronary angiography or intervention is associated with substantial morbidity. The data supporting various prophylactic measures and adjunctive therapies to prevent this complication are conflicting. However, contrast volume is clearly related to CIN after pe...

Full description

Saved in:

Bibliographic Details
Published in:	Catheterization and cardiovascular interventions Vol. 75; no. 7; pp. 1076 - 1083
Main Authors:	Nayak, Keshav R., Mehta, Hirsch S., Price, Matthew J., Russo, Robert J., Stinis, Curtiss T., Moses, Jeffrey W., Mehran, Roxana, Leon, Martin B., Kandzari, David E., Teirstein, Paul S.
Format:	Journal Article
Language:	English
Published:	Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-06-2010
Subjects:	Aged Aged, 80 and over Angioplasty, Balloon, Coronary - instrumentation Biomarkers - blood Chronic Disease Cineangiography Contrast Media - administration & dosage Contrast Media - adverse effects Coronary Angiography Coronary Artery Disease - complications Coronary Artery Disease - diagnostic imaging Coronary Artery Disease - therapy Creatinine - blood Female Glomerular Filtration Rate Humans Kidney Diseases - complications Kidney Diseases - physiopathology Male Middle Aged Radiography, Interventional Stents Treatment Outcome Ultrasonography, Interventional
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Contrast‐induced nephropathy (CIN) after coronary angiography or intervention is associated with substantial morbidity. The data supporting various prophylactic measures and adjunctive therapies to prevent this complication are conflicting. However, contrast volume is clearly related to CIN after percutaneous coronary intervention (PCI), and the risk of CIN has been shown to be directly related to contrast dose. Therefore, minimizing contrast exposure is a primary method to reduce the risk of CIN, especially in at‐risk patients. We report a novel technique designed to deliver ultra‐low (<15 cm3) volume contrast to patients with chronic kidney disease undergoing coronary angiography and PCI. © 2010 Wiley‐Liss, Inc.
Bibliography:	istex:903A3E2EC130B2F851DC691B9EE3AEE668781D45 ArticleID:CCD22414 Conflict of interest: All authors have read and approved submission of the manuscript. The manuscript has not been published and is not being considered for publication elsewhere in whole or part in any language. Dr. Leon reports having received consultation fees from Medtronic, Abbott, Boston Scientific, and Volcano Therapeutics, Dr. Mehran reports receiving consultation and speaker's honoraria from The Medicines Company, Lilly/Diachi Sankyo, Sanofi/Aventis, Medtronic Vascular, Abbott Vascular, Cordis, Boston Scientific, Guerbert, and Bracco, and holds Equity interest in Flow Medica, and Square one. Dr. Russo reports having received an unrestricted educational grant and speakers honoraria from Boston Scientific Corporation, Dr. Kandzari reports having received research/grant support from Medtronic CardioVascular and Cordis Corporation and consulting honoraria from Medtronic, CardioVascular, and Cordis Corporation, and Dr. Teirstein is a consultant for and receives research grants from Boston Scientific, Medtronic and Abbott. All other authors report no conflicts of interest. ark:/67375/WNG-ZRQ0TZH3-F ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1522-1946 1522-726X
DOI:	10.1002/ccd.22414